Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
From Fledgling to Master: Self-awareness in a Side interest- Lucrative Positions in the Advancing Position Market of 2024
- Find the Lively Food Markets of South America
- Figure out How to Forestall Tooth Staining
- 10 Hints for an Effective New employee screening
- Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- My Pioneering Excursion: Building a Startup
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
